An interesting trial centred on SW USA. The use of CAPTEM following surgery in high-risk pancreatic NETs (G2/G3 well-differentiated). Also includes the use of NETest at 3 time points, which is very interesting considering the recent withdrawal of Chromogranin A from US NET Guidelines. (Read about NETest here).
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors (S2104) is a recently activated National Clinical Trials Network randomized phase II trial designed to compare CAPTEM chemotherapy versus observation following resection of pNETs (see Figure 2). Patients with well-differentiated grade 2 or 3 (Ki-67 up to 55%) pNETS with a Zaidi score of ≥3 who underwent resection (or ablation) for either localized disease with or without up to five liver metastases are eligible for enrollment. Patients must be older than 18 years of age, have a Zubrod performance status of 0–2, and have adequate bone marrow function. Prior neoadjuvant therapy for treatment of pancreatic neuroendocrine tumor is prohibited, with the exception of prior somatostatin analog use. Stratification factors for randomization are disease status before resection (metastatic versus nonmetastatic) and Zaidi score (≥6 versus <6 versus not applicable due to presence of metastatic disease).
FIGURE 2. Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Vs. Observation In High-Risk pNET: Swog S2104
The primary outcome is recurrence-free survival. Patients will be followed with cross-sectional imaging every 6 months for the first 3 years postresection and every 12 months for the next 2 years, for a total of 5 years of surveillance. To facilitate access to the trial, telehealth visits will be allowed in the first 4 months of enrollment for amenable visits. Correlative studies will be performed on banked blood and tissue. The S2014 trial will address a major knowledge gap in clinical practice, specifically the role of adjuvant therapy in patients undergoing resection for high-risk pNETs. If this study demonstrates that CAPTEM reduces recurrence, it will change the standard of care for this disease.
For more information, contact principal investigator of the trial, Heloisa Soares, MD, PhD, Heloisa.email@example.com.
Read more here:
1. Bulletin of the American College of Surgeons: Clinical Trial Examines Postoperative Chemotherapy versus Observation in High-Risk Pancreatic Neuroendocrine Tumors by HELOISA SOARES, REBECCA A. SNYDER, MD, MPH, FACS, JUDY C. BOUGHEY, MD, FACS AND FLAVIO G. ROCHA, MD, FACS published Mar 4, 2022 • – click here.
2. ClinicalTrials.gov Identifier: NCT05040360 – click here.
Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.
Inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Subscribe to my newsletter
Top 10 Posts & Pages in the last 48 hours (auto updates)
Thanks for reading.
Sign up for my newsletters – Click Here